Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
15,733
datasets available to search
ShareScore release 0.9.0
Dataset results
15,733 results for “article”
Dataset related to article "Independent expression of circulating and tissue levels of PD-L1: correlation of clusters with tumor metabolism and outcome in patients with non-small cell lung cancer."
<p>PURPOSE:</p> <p>To evaluate the clinical-pathological and prognostic significance of the circulating PD-L1 level in patients with surgically treated NSCLC, by combining data for PD-L1 expression with other immune-related markers and tumor metabolism.</p> <p>METHODS:</p> <p>Overall, 40 patients with resected NSCLC (stage Ia-IIIa) who had preoperative blood storage and underwent staging PET/CT were enrolled for the study. In all cases, we determined plasma levels of PD-L1 (pg/ml), immune-reactive areas (IRA %) covered by CD3, CD68, CD20, CD8, PD-1, and PD-L1 in the tumor specimen, and metabolic parameters on PET, i.e., SUV<sub>max</sub>, SUV<sub>peak</sub>, metabolic tumor volume (MTV), and total lesion glycolysis (TLG). Variables were statistically analyzed to establish their association with disease-free survival (DFS).</p> <p>RESULTS:</p> <p>The circulating levels of PD-L1 in the bloodstream could be determined in 38/40 (95%) samples. The mean and median expression levels were 34.86 pg/ml and 24.83 pg/ml, respectively. We did not find any statistically significant correlation between circulating PD-L1 and tissue expression of PD-L1/PD-1. Some mild degree of positive correlation was determined between tissue PD-L1 and SUV<sub>max</sub> (ρ =&thinsp;0.390; p =&thinsp;0.0148). Hierarchical clustering combining circulating, tissue, and metabolic parameters identified clusters with high metabolic tumor burden or high expression of plasma PD-L1 levels (Z score ≥ 2) as having a poor DFS (p =&thinsp;0.033). The multivariate analysis detected stage and metabolism (i.e., SUV<sub>max</sub> and SUV<sub>peak</sub>) as independent prognostic factors for DFS.</p> <p>CONCLUSION:</p> <p>Plasma levels of PD-L1 are independent of the expression of PD-1/PD-L1 in NSCLC tumor tissue and, when combined with other clinical-pathological parameters, allow for the identification of clusters with different outcomes.</p>
Dataset related to article "Predictive and Prognostic Role of Metabolic Response in Patients With Stage III NSCLC Treated With Neoadjuvant Chemotherapy."
<p>INTRODUCTION:</p> <p>The purpose of this study was to assess the predictive and prognostic role of 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) in candidates with stage III non-small-cell lung cancer (NSCLC) to neoadjuvant chemotherapy.</p> <p>PATIENTS AND METHODS:</p> <p>Sixty-six patients with stage III NSCLC treated with induction chemotherapy from March 2013 to December 2017 were retrospectively identified. Response assessment were evaluated according to the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 and European Organisation for Research and Treatment of Cancer (EORTC) criteria. 18F-FDG PET/CT metabolic parameters were analyzed as absolute values as well as percentage changes (Δ) between 2 consecutive scans, for primary tumor (T) and for regional lymph nodes (N). All clinical variables and metabolic parameters were compared with treatment response and correlated with progression-free survival (PFS) and overall survival (OS), based on a median follow-up of 9.4 months.</p> <p>RESULTS:</p> <p>Post-induction therapy standardized uptake value (SUV)max_T, SUVmean_T, metabolic tumor volume (MTV_T), and total lesion glycolysis of the tumor (TLG_T) varied significantly between responders and non-responders (6.6 vs. 13.8; P = .001; 4.2 vs. 8.1; P < .001; 6 vs. 17.9; P = .002; and 24.1 vs. 136.3; P < .001, respectively). Likewise, percentage changes (Δ_T) were significantly different between the 2 groups (P < .001). Along with primary tumor, also post-SUVmax_N, post-SUVmean_N, and post-TLG_N (P = .024, P = .015, and P = .024, respectively), as well as all percentage changes (Δ_N) were different between responders and non-responders. RECIST 1.1 and EORTC response classifications were discordant in 27 patients (40.9%; κ = 0.265; P = .003). On multivariate analysis, post-TLG_N was an independent predictor for both PFS and OS, whereas RECIST 1.1 was a predictor only for OS.</p> <p>CONCLUSIONS:</p> <p>Several metabolic parameters may differentiate responders from non-responders following neoadjuvant chemotherapy in stage III NSCLC. As compared with RECIST 1.1, EORTC seems to be more appropriate for evaluation therapeutic response. Finally, post-TLG_N has significant prognostic information.</p>
Dataset related to article "Donor-Specific Anti-HLA Antibodies in Haploidentical Stem Cell Transplantation with Post-Transplantation Cyclophosphamide: Risk of Graft Failure, Poor Graft Function, and Impact on Outcomes."
<p>The presence of donor-specific anti-HLA antibodies (DSA) is associated with a 10-fold increased risk of graft failure in haploidentical stem cell transplantation (haplo-SCT). Consensus guidelines from the European Society for Blood and Marrow Transplantation set a mean fluorescence intensity (MFI) >1000 as a cutoff for DSA positivity. In the absence of an alternative donor, it is recommended that patients undergo desensitization therapy, especially with high DSA levels (>5000 MFI). The aim of this study was to analyze the impact of DSA on risk of graft failure and poor graft function, as well as on major outcomes in a consecutive cohort of patients who were systematically screened for DSA before haplo-SCT. A total of 141 consecutive patients were candidates for unmanipulated haplo-SCT with post-transplantation cyclophosphamide (PT-Cy) at our center between January 2012 and January 2018, and 135 were analyzed for the presence of HLA antibodies. Of these 134 patients underwent haplo-SCT. HLA antibodies were detected in 40 patients, including 19 with DSA and 21 without DSA. Ten of the 19 patients with DSA underwent transplantation using that donor, whereas 2 underwent a desensitization program before transplantation. Only 2 patients experienced primary graft failure (1.4 %), both of whom were without DSA. Twenty patients developed a poor graft function (15%). The 3-year overall survival (OS), 3-year progression-free survival (PFS), and 1-year nonrelapse mortality (NRM) were analyzed according to the presence or absence of DSA. No statistically significant difference was found. No impact of the presence of DSA on the risk of developing graft failure and poor graft function was revealed. Major outcomes of transplantation were analyzed separately in patients with poor graft function and those with good graft function. The 3-year OS, 3-year PFS, and 1-year NRM in good graft function and poor graft function populations were 62% versus 20% (P < .0001), 53% versus 20% (P < .0001), and 12% versus 40% (P = .009), respectively. The presence of low-level DSA in the absence of desensitization did not correlate with the risk of developing graft failure and poor graft function. Patients who experienced poor graft function had worse outcomes than patients with good graft function.</p>
Dataset related to article: "Intensity modulated proton therapy compared to volumetric modulated arc therapy in the irradiation of young female patients with hodgkin's lymphoma. Assessment of risk of toxicity and secondary cancer induction"
<p>This record contains data related to article: "Intensity modulated proton therapy compared to volumetric modulated arc therapy in the irradiation of young female patients with hodgkin's lymphoma. Assessment of risk of toxicity and secondary cancer induction"</p> <p>Abstract</p> <p><strong>Background: </strong> To investigate the role of intensity modulated proton therapy (IMPT) compared to volumetric modulated arc therapy (VMAT) for advanced supradiaphragmatic Hodgkin's lymphoma (HL) in young female patients by assessing dosimetric features and modelling the risk of treatment related complications and radiation-induced secondary malignancies.</p> <p><strong>Methods: </strong> A group of 20 cases (planned according to the involved-site approach) were retrospectively investigated in a comparative planning study. Intensity modulated proton plans (IMPT) were compared to VMAT RapidArc plans (RA). Estimates of toxicity were derived from normal tissue complication probability (NTCP) calculations with either the Lyman or the Poisson models for a number of endpoints. Estimates of the risk of secondary cancer induction were determined for lungs, breasts, esophagus and thyroid. A simple model-based selection strategy was considered as a feasibility proof for the individualized selection of patients suitable for proton therapy.</p> <p><strong>Results: </strong> IMPT and VMAT plans resulted equivalent in terms of target dose distributions, both were capable to ensure high coverage and homogeneity. In terms of conformality, IMPT resulted ~ 10% better than RA plans. Concerning organs at risk, IMPT data presented a systematic improvement (highly significant) over RA for all organs, particularly in the dose range up to 20Gy. This lead to a composite average reduction of NTCP of 2.90 ± 2.24 and a reduction of 0.26 ± 0.22 in the relative risk of cardiac failures. The excess absolute risk per 10,000 patients-years of secondary cancer induction was reduced, with IMPT, of 9.1 ± 3.2, 7.2 ± 3.7 for breast and lung compared to RA. The gain in EAR for thyroid and esophagus was lower than 1. Depending on the arbitrary thresholds applied, the selection rate for proton treatment would have ranged from 5 to 75%.</p> <p><strong>Conclusion: </strong> In relation to young female patients with advanced supradiaphragmatic HL, IMPT can in general offer improved dose-volume sparing of organs at risk leading to an anticipated lower risk of early or late treatment related toxicities. This would reflect also in significantly lower risk of secondary malignancies induction compared to advanced photon based techniques. Depending on the selection thresholds and with all the limits of a non-validated and very basic model, it can be anticipated that a significant fraction of patients might be suitable for proton treatments if all the risk factors would be accounted for.</p> <p> </p>
The POLUSA Dataset: 0.9M Political News Articles Balanced by Time and Outlet Popularity
<p>The POLUSA dataset, as presented at the ACM/IEEE Joint Conference on Digital Libraries in August 2020 (JCDL '20)</p>
Data file for Rey et al.'s article, "Sex and age-related social organization in the Neolithic: A promising survey from the Paris Basin".
<p>Supporting data file for Rey et al.'s article, "Sex and age-related social organization in the Neolithic: A promising survey from the Paris Basin", published in 2021 in <em>Journal of Archaeological Science: Reports</em>. doi: <a href="https://doi.org/10.1016/j.jasrep.2021.103092">10.1016/j.jasrep.2021.103092</a>.</p>
Drug-interaction annotations over full text articles reporting on clinical studies reports or case reports
<p>Drug interaction annotations over full text reports. These annotations were done as part of the National Library of Medicine funded research project "Addressing gaps in clinically useful evidence on drug-drug interactions" (R01LM011838)</p>
Dataset related to the article "Predictive Value of Pre‐Operative 2D and 3D Transthoracic Echocardiography in Patients Undergoing Mitral Valve Repair: Long Term Follow Up of Mitral Valve Regurgitation Recurrence and Heart Chamber Remodeling"
<p>This record contains raw data related to the article "Predictive Value of Pre‐Operative 2D and 3D Transthoracic Echocardiography in Patients Undergoing Mitral Valve Repair: Long Term Follow Up of Mitral Valve Regurgitation Recurrence and Heart Chamber Remodeling"</p> <p><strong>Abstract</strong>: The “ideal” management of asymptomatic severe mitral regurgitation (MR) in valve<br> prolapse (MVP) is still debated. The aims of this study were to identify pre‐operatory parameters<br> predictive of residual MR and of early and long‐term favorable remodeling after MVP repair. We<br> included 295 patients who underwent MV repair for MVP with pre‐operatory two‐ and threedimensional<br> transthoracic echocardiography (2DTTE and 3DTTE) and 6‐months (6M) and 3‐years<br> (3Y) follow‐up 2DTTE. MVP was classified by 3DTTE as simple or complex and surgical procedures<br> as simple or complex. Pre‐operative echo parameters were compared to post‐operative values at 6M<br> and 3Y. Patients were divided into Group 1 (6M‐MR < 2) and Group 2 (6M‐MR ≥ 2), and predictors<br> of MR 2 were investigated. MVP was simple in 178/295 pts, and 94% underwent simple<br> procedures, while in only 42/117 (36%) of complex MVP a simple procedure was performed. A<br> significant relation among prolapse anatomy, surgical procedures and residual MR was found. Postoperative<br> MR ≥ 2 was present in 9.8%: complex MVP undergoing complex procedures had twice the<br> percentage of MR ≥ 2 vs. simple MVP and simple procedures. MVP complexity resulted<br> independent predictor of 6M‐MR ≥ 2. Favorable cardiac remodeling, initially found in all cases, was<br> maintained only in MR < 2 at 3Y. Pre‐operative 3DTTE MVP morphology identifies pts undergoing<br> simple or complex procedures predicting MR recurrence and favorable cardiac remodeling.</p>
Databases of "Economic criteria of Policosanol extraction" article: standardization, merge and removing duplication of results found in the Scopus Elsevier and Web of Science bases
<p>These eight databases derives from the processes of standardization, merge and removing duplication of results found in the Scopus Elsevier and Web of Science bases, in CSV format to be used with software suitable for replicating the results, new statistical, bibliometric, semantic and other treatments.</p> <p>DatabaseE1 - Extraction - BUSINESS ATTRACTIVENESS. </p> <p>DatabaseE2 - Extraction - COMMERCIAL AND EXPORT FEASIBILITY </p> <p>DatabaseE3 - Extraction - TECHNICAL AND INDUSTRIAL VIABILITY: </p> <p>DatabaseE4 - Extraction - ECOEFICIENCY</p> <p>DatabaseEG1 - General - BUSINESS ATTRACTIVENESS </p> <p>DatabaseEG2 - General - COMMERCIAL AND EXPORT FEASIBILITY </p> <p>DatabaseEG3 - General - TECHNICAL AND INDUSTRIAL VIABILITY: </p> <p>DatabaseEG4 - General - ECOEFICIENCY</p> <p>It is constitutive of the article entitled " Economic criteria of Policosanol extraction: a systematic literature review and patent prospection", by professors Rilton Gonçalo Bonfim Primo, Jesus Martín-Gil, Fernando Cardoso Pedrão, Carlos Narciso Bouza and Ricardo de Araújo Kalid.</p>
Dataset related to article "Computed tomography (CT)-derived radiomic features differentiate prevascular mediastinum masses as thymic neoplasms versus lymphomas"
<p>This record contains raw data related to article "Computed tomography (CT)-derived radiomic features differentiate prevascular mediastinum masses as thymic neoplasms versus lymphomas"</p> <p><strong>Objectives: </strong>We aimed to assess the ability of radiomics, applied to not-enhanced computed tomography (CT), to differentiate mediastinal masses as thymic neoplasms vs lymphomas.</p> <p><strong>Methods: </strong>The present study was an observational retrospective trial. Inclusion criteria were pathology-proven thymic neoplasia or lymphoma with mediastinal localization, availability of CT. Exclusion criteria were age < 16 years and mediastinal lymphoma lesion < 4 cm. We selected 108 patients (M:F = 47:61, median age 48 years, range 17-79) and divided them into a training and a validation group. Radiomic features were used as predictors in linear discriminant analysis. We built different radiomic models considering segmentation software and resampling setting. Clinical variables were used as predictors to build a clinical model. Scoring metrics included sensitivity, specificity, accuracy and area under the curve (AUC). Wilcoxon paired test was used to compare the AUCs.</p> <p><strong>Results: </strong>Fifty-five patients were affected by thymic neoplasia and 53 by lymphoma. In the validation analysis, the best radiomics model sensitivity, specificity, accuracy and AUC resulted 76.2 ± 7.0, 77.8 ± 5.5, 76.9 ± 6.0 and 0.84 ± 0.06, respectively. In the validation analysis of the clinical model, the same metrics resulted 95.2 ± 7.0, 88.9 ± 8.9, 92.3 ± 8.5 and 0.98 ± 0.07, respectively. The AUCs of the best radiomic and the clinical model not differed.</p> <p><strong>Conclusions: </strong>We developed and validated a CT-based radiomic model able to differentiate mediastinal masses on non-contrast-enhanced images, as thymic neoplasms or lymphoma. The proposed method was not affected by image postprocessing. Therefore, the present image-derived method has the potential to noninvasively support diagnosis in patients with prevascular mediastinal masses with major impact on management of asymptomatic cases.</p> <p> </p>
Dataset related to article "Work Ability Assessment and Its Relationship with Cardiovascular Autonomic Profile in Postural Orthostatic Tachycardia Syndrome"
<p>This record contains raw data related to article “ Work Ability Assessment and Its Relationship with Cardiovascular Autonomic Profile in Postural Orthostatic Tachycardia Syndrom"</p> <p>Postural orthostatic tachycardia syndrome (POTS) negatively impacts quality of life. The excessive increase in cardiac sympathetic modulation during standing, which characterizes POTS patients, leads to many symptoms and signs of orthostatic intolerance. Little is known about the consequences of the disease on work performance and its relationship with individual autonomic profiles. Twenty-two POTS patients regularly engaged in working activity (20 females, age 36 ± 12 years) and 18 gender- and age-matched controls underwent a clinical evaluation and filled out the Work Ability Index (WAI) questionnaire. POTS patients completed the Composite Autonomic Symptom Score (COMPASS31) questionnaire, underwent continuous electrocardiogram, blood pressure and respiratory activity recordings while supine and during a 75° head-up tilt (HUT). A power spectrum analysis provided the index of cardiac sympatho-vagal balance (LF/HF). WAI scores were significantly reduced in POTS patients (29.84 ± 1.40) compared to controls (45.63 ± 0.53, p < 0.01). A significant inverse correlation was found between individual WAI and COMPASS31 scores (r = -0.46; p = 0.03), HUT increase in heart rate (r = -0.57; p = 0.01) and LF/HF (r = -0.55; p = 0.01). In POTS patients, the WAI scores were inversely correlated to the intensity of autonomic symptoms and to the excessive cardiac sympathetic activation induced by the gravitational stimulus.</p>
Dataset related to article: "Are Strategies Favoring Pattern Matching a Viable Way to Improve Complexity Estimation Based on Sample Entropy?"
<p>This record contains data related to article "Are Strategies Favoring Pattern Matching a Viable Way to Improve Complexity Estimation Based on Sample Entropy?"</p> <p>It has been suggested that a viable strategy to improve complexity estimation based on</p> <p>the assessment of pattern similarity is to increase the pattern matching rate without enlarging the</p> <p>series length. We tested this hypothesis over short simulations of nonlinear deterministic and linear</p> <p>stochastic dynamics affected by various noise amounts. Several transformations featuring a</p> <p>different ability to increase the pattern matching rate were tested and compared to the usual strategy</p> <p>adopted in sample entropy (SampEn) computation. The approaches were applied to evaluate the</p> <p>complexity of short-term cardiac and vascular controls from the beat-to-beat variability of heart</p> <p>period (HP) and systolic arterial pressure (SAP) in 12 Parkinson disease patients and 12 age- and</p> <p>gender-matched healthy subjects at supine resting and during head-up tilt. Over simulations, the</p> <p>strategies estimated a larger complexity over nonlinear deterministic signals and a greater</p> <p>regularity over linear stochastic series or deterministic dynamics importantly contaminated by</p> <p>noise. Over short HP and SAP series the techniques did not produce any practical advantage, with</p> <p>an unvaried ability to discriminate groups and experimental conditions compared to the traditional</p> <p>SampEn. Procedures designed to artificially increase the number of matches are of no</p> <p>methodological and practical value when applied to assess complexity indexes.</p>
Technical report with partial results of the article "Technological routes of Policosanols extraction"
<p>It is constitutive of the article entitled "Technological routes of Policosanols extraction: a systematic literature review and patent prospection", by professors Rilton Gonçalo Bonfim Primo, Jesus Martín-Gil, Fernando Cardoso Pedrão, Carlos Narciso Bouza and Ricardo de Araújo Kalid.</p> <p>In the Table 1, Table 2 and Table 3 one care taken was to carry out the “Extended Search” (i.e., in all fields of the articles, not just in the title, abstract and keywords) in cases where the results were less than ten. This inclusiveness naturally implies refiltering articles outside the scope of the research. Policosanol spelling variants, with "y" or "i", and suffix variations “ultrasonic” or “ultrasound” were considered in these searches.</p> <p>Methodological, computational and bibliometric aspects, as well as their historical, research, discussions and inferences contexts can be found in the referred article, of which this document is only a data repository of leading partial results, through quantitative and qualitative analyzes, to the final results achieved there.</p>
Dataset related to article "Macrophage morphology of tumor-associated macrophages as a correlate of metabolism with prognostic significance in colorectal liver metastases"
<p>This record contains data related to article "Morphology of tumor-associated macrophages as a correlate of metabolism with prognostic significance in colorectal liver metastases"</p> <p>Abstract</p> <p>It has long been known that in vitro polarized macrophages differ in morphology. Stemming from a conventional immunohistology observation, we set out to test the hypothesis that morphology of tumor-associated macrophages (TAMs) in colorectal liver metastasis (CLM) represents a correlate of functional diversity with prognostic significance. Density and morphological metrics of TAMs were measured and correlated with clinicopathological variables. While density of TAMs did not correlate with survival of CLM patients, the cell area identified small (S-TAM) and large (L-TAM) macrophages that were associated with 5-yr disease-free survival rates of 27.8% and 0.2%, respectively (P < 0.0001). RNA sequencing of morphologically distinct macrophages identified LXR/RXR as the most enriched pathway in large macrophages, with upregulation of genes involved in cholesterol metabolism, scavenger receptors, MERTK, and complement. In single-cell analysis of mononuclear phagocytes from CLM tissues, S-TAM and L-TAM signatures were differentially enriched in individual clusters. These results suggest that morphometric characterization can serve as a simple readout of TAM diversity with strong prognostic significance.</p>
Dataset related to article "Immune infiltrating cells in duodenal cancers"
<p>This record contains data related to article "Immune infiltrating cells in duodenal cancers"</p> <p> </p> <p>Abstract.</p> <p> Background: Duodenal adenocarcinoma (DA) is a rare yet aggressive malignancy, with increasing incidence in the</p> <p>last decades. Its low frequency has hampered a thorough understanding of the pathogenesis of the disease and of</p> <p>its biology, limiting the identification of tailored therapeutic options. A large body of evidence has clearly shown the</p> <p>clinical relevance of immune cells in solid tumors, correlating immune features with post-surgical prognosis. The aim</p> <p>of this study was to analyze the immune contexture in a cohort of duodenal adenocarcinomas surgically resected at</p> <p>our Institution and define its correlation with clinical variables.</p> <p> Methods: Tissue slides from paraffin-embedded tumor specimens of 15 consecutive DA and 3 adenomas that</p> <p>underwent a pancreaticoduodenectomy in our center between 2010 to 2018 were immunohistochemically stained.</p> <p>The density (percentage of immune reactive area, IRA%) of immune markers CD45RO, CD8, CD20, IL-17, PD-1, CD68</p> <p>was quantified by computer-assisted image analysis. Demographic, clinical, histopathological data were collected.</p> <p> Results: In our population, median IRA % (IQR) of immune subsets was respectively CD45RO-TILs 2.19 (2.14), CD8-TIL</p> <p>0.42 (0.81), CD20-TILs 0.22 (0.51), CD20-TLT 2.84 (4.64), CD68-TAM 2.19 (1.56), IL17+</p> <p>cells 0.39 (0.39), PD1-TILs 0.19 (0.41).</p> <p>The median follow-up was 47.5 (22.4–63.3) months. At statistical analysis, the density of CD8-TILs inversely correlated</p> <p>with lymph node ratio (p = 0.013), number of metastatic lymph nodes (p = 0.019), and was lower in N+ adenocarcinomas</p> <p>compared to N0 (1.07 vs 0.29; p = 0.093), albeit not significantly. Stratifying patients for the N status, the density of</p> <p>CD8-TILs decreased with the increasing of the N stage (p = 0.065) and was lower in patients who experienced recurrence</p> <p>and died for the disease (0.276 vs 0.641; p = 0.044). Notably, also CD68-TAM distribution was different in patients</p> <p>who had recurrence versus patients who did not (1.028 vs 2.276; p = 0.036).</p> <p> Conclusions: Immune cells showed variable expression in correlation with common prognostic factors, suggesting</p> <p>T cell infiltration may play a protective role towards lymphatic spread of disease and nodal metastatization. Furthermore,</p> <p>T cell density and macrophage infiltration were associated to a lower risk of recurrence and disease related</p> <p>death. A multicentric approach may be indicated to allow analysis of larger cohorts of patients, potentially increasing</p> <p>the power of our observations.</p>
Dataset related to article "Metabolome of Pancreatic Juice Delineates Distinct Clinical Profiles of Pancreatic Cancer and Reveals a Link between Glucose Metabolism and PD-1+ Cells"
<p>This record contains data related to the article "Metabolome of Pancreatic Juice Delineates Distinct Clinical Profiles of Pancreatic Cancer and Reveals a Link between Glucose Metabolism and PD-1+ Cells".</p> <p>Better understanding of pancreatic diseases, including pancreatic ductal adenocarcinoma (PDAC), is an urgent medical need, with little advances in preoperative differential diagnosis, preventing rational selection of therapeutic strategies. The clinical management of pancreatic cancer patients would benefit from the identification of variables distinctively associated with the multiplicity of pancre- atic disorders. We investigated, by 1H nuclear magnetic resonance, the metabolomic fingerprint of pancreatic juice (the biofluid that collects pancreatic products) in 40 patients with different pancreatic diseases. Metabolic variables discriminated PDAC from other less aggressive pancreatic diseases and identified metabolic clusters of patients with distinct clinical behaviors. PDAC specimens were overtly glycolytic, with significant accumulation of lactate, which was probed as a disease-specific variable in pancreatic juice from a larger cohort of 106 patients. In human PDAC sections, high expression of the glucose transporter GLUT-1 correlated with tumor grade and a higher density of PD-1+ T cells, suggesting their accumulation in glycolytic tumors. In a preclinical model, PD-1+ CD8 tumor–infiltrating lymphocytes differentially infiltrat- ed PDAC tumors obtained from cell lines with different metabolic consumption, and tumors metabolically rewired by knocking down the phosphofructokinase (Pfkm) gene displayed a decrease in PD-1+ cell infiltration. Collectively, we introduced pancreatic juice as a valuable source of metabolic variables that could contri- bute to differential diagnosis. The correlation of metabolic markers with immune infiltration suggests that upfront evaluation of the metabolic profile of PDAC patients could foster the introduction of immunotherapeutic approaches for pancreatic cancer.</p> <p> </p>
Dataset related to article "Immunotherapy in Hepatocellular Cancer Patients with Mild to Severe Liver Dysfunction: Adjunctive Role of the ALBI Grade"
<p>This report contains raw data related to article "<em>Immunotherapy in Hepatocellular Cancer Patients with Mild to Severe Liver Dysfunction: Adjunctive Role of the ALBI Grade".</em></p> <p>Immune checkpoint inhibitors (ICI) have shown positive results in patients with hepatocellular carcinoma (HCC). As liver function contributes to prognosis, its precise assessment is necessary for the safe prescribing and clinical development of ICI in HCC. We tested the accuracy of the albumin-bilirubin (ALBI) grade as an alternative prognostic biomarker to the Child-Turcotte-Pugh (CTP). In a prospectively maintained multi-centre dataset of HCC patients, we assessed safety and efficacy of ICI across varying levels of liver dysfunction described by CTP (A to C) and ALBI grade and evaluated uni- and multi-variable predictors of overall (OS) and post-immunotherapy survival (PIOS). We studied 341 patients treated with programmed-death pathway inhibitors (<em>n</em> = 290, 85%). Pre-treatment ALBI independently predicted for OS, with median OS of 22.5, 9.6, and 4.6 months across grades (<em>p</em> < 0.001). ALBI was superior to CTP in predicting 90-days mortality with area under the curve values of 0.65 (95% CI 0.57-0.74) versus 0.63 (95% CI 0.54-0.72). ALBI grade at ICI cessation independently predicted for PIOS (<em>p</em> < 0.001). Following adjustment for ICI regimen, neither ALBI nor CTP predicted for overall response rates or treatment-emerging adverse events (<em>p</em> > 0.05). ALBI grade identifies a subset of patients with prolonged survival prior to and after ICI therapy, lending itself as an optimal stratifying biomarker to optimise sequencing of systemic therapies in advanced HCC.</p>
Dataset related to article "Stereotactic Body Radiation Therapy in the Management of Oligometastatic and Oligoprogressive Bladder Cancer and Other Urothelial Malignancies"
<p>This record contains raw data related to article "Stereotactic Body Radiation Therapy in the Management of Oligometastatic and Oligoprogressive Bladder Cancer and Other Urothelial Malignancies"</p> <p><strong>Aims: </strong>Bladder cancer represents the most common type of urothelial carcinoma, with a median overall survival of 12.5-15 months in the case of metastatic disease. We evaluated the role of stereotactic body radiation therapy (SBRT) in the management oligometastatic urothelial cancer.</p> <p><strong>Materials and methods: </strong>Data on patients with a maximum of five metastases were collected from three institutions. Concomitant systemic therapy was allowed. End points were the local control of treated metastases, distant progression-free survival (PFS), overall PFS and overall survival.</p> <p><strong>Results: </strong>Data for 82 lesions and 61 patients were included. The primary tumour was located in the bladder in 82% of patients, followed by kidney pelvis (11.5%). The most common treated site was lung (40.2%). Twenty-nine (47.5%) and 14 (23%) patients received systemic therapy before and during SBRT, respectively. The median BED10 value was 78.7 Gy. The median follow-up was 17.2 months. Rates of local control at 1 and 2 years were 92% and 88.9%, respectively, with correlation with systemic therapy before SBRT (hazard ratio 2.62, P = 0.034). Overall PFS at 1 and 2 years was 47.9% and 38.1%, respectively. The number of metastases was a predictive factor (hazard ratio 2.65, P = 0.008). The median overall survival was 25.6 months. Total dose (hazard ratio 0.93, P = 0.003) and BED10 (hazard ratio 0.97, P = 0.006) were correlated with overall survival. No grade ≥2 adverse events were reported.</p> <p><strong>Conclusions: </strong>SBRT represents an effective and safe treatment in metastatic urothelial carcinoma. Prospective randomised trials are necessary to better evaluate the benefit on delaying the onset of new systemic therapies.</p>
Dataset related to article "Recursive partitioning model-based analysis for survival of colorectal cancer patients with lung and liver oligometastases treated with stereotactic body radiation therapy"
<p>This record contains raw data related to article “Recursive partitioning model-based analysis for survival of colorectal cancer patients with lung and liver oligometastases treated with stereotactic body radiation therapy"</p> <p><strong>Introduction: </strong>Liver and lung are common sites of metastases from colorectal cancer (CRC). Stereotactic body radiation therapy (SBRT) represents a valid treatment, with high rates of local control (LC). In this study, we applied recursive partitioning model-based analysis (RPA) to define class risks for overall survival (OS) and progression free survival (PFS) in oligometastatic CRC patients.</p> <p><strong>Materials and methods: </strong>In this monocentric analysis, we included patients with lung or liver metastases. Patients were candidate to SBRT if a maximum of 5 metastases. End points of the present analysis were LC, PFS, and OS. The binary classification tree approach with RPA was applied to stratify the patients into risk groups based on OS and PFS.</p> <p><strong>Results: </strong>218 patients were treated with SBRT on 371 metastases. Majority of patients (56%) was treated on single lesion, followed by 2 (26.1%) and 3 lesions (14.7%). Median follow-up was 22.7 months. Rates of LC were 84.2% at 1 year and 73.8% at 3 years. Rates of PFS at 1 and 3 years were 42.2% and 14.9%, respectively. RPA identified 3 classes for PFS, according to age and number of metastases with 3-year PFS of 30.6%, 13.5% and 8.4%. Overall survival was 87.2% at 1 year, 51.9% at 3 years, and 36.8% at 5 years. RPA identified 3 nodes. Class 1 included patients with liver metastases (3-year OS 35.2%). Class 2 included patients with lung metastases and DFI ≤ 48 months (3-year OS 65%). Class 3 included patients with lung metastases and DFI > 48 months (3-year OS 73.5%).</p> <p><strong>Conclusions: </strong>Stereotactic body radiation therapy can be considered an effective treatment for the management of liver and lung metastases from CRC. With RPA, we identified prognostic risk class to define patients who could benefit the most from SBRT.</p>
Dataset related to article "Liver Metastases-directed Therapy in the Management of Oligometastatic Breast Cance"
<p>This record contains raw data related to article “Liver Metastases-directed Therapy in the Management of Oligometastatic Breast Cance"</p> <p><strong>Introduction: </strong>In the context of metastatic breast cancer, dissemination to the liver is a frequent occurrence. We aimed to evaluate the outcome and toxicity of metastatic breast cancer with liver oligometastases treated with metastases-directed therapies (MDTs), including surgery, stereotactic body radiation therapy, or thermal ablation (radiofrequency or microwaves).</p> <p><strong>Patients and methods: </strong>We included patients with diagnosis of 1 to 5 liver metastases. Selection criteria included also age > 18 years; Eastern Cooperative Oncology Group performance status 0 to 2; absence of extra-hepatic disease or other controlled metastatic sites. Endpoints were liver progression-free survival (LPFS), progression-free survival (PFS), and overall survival.</p> <p><strong>Results: </strong>A total of 72 patients were included. Previous local treatments were performed in 13 (18.1%) patients, whereas systemic therapy was used in 81.9% of cases. Treatment of choice was stereotactic body radiation therapy in 54 (75%) patients followed by surgery (13 patients; 18%) and thermal ablation (5 patients; 7%). With a median follow-up of 26.2 months, LPFS at 1 and 2 years was 52.4% and 38.8%, respectively. The number of metastases predicted LPFS (hazard ratio [HR], 1.70; P = .004). Rates of PFS were 38.7% and 22% at 1 and 2 years, respectively. Systemic therapy before MDT (HR, 2.89; P = .016) was correlated with PFS. Overall survival at 1 and 2 years was 95.5% and 76.9%, respectively. Human epidermal growth factor receptor 2 status correlated with survival (HR, 1.82; P = .010).</p> <p><strong>Conclusion: </strong>Combination of systemic therapy with liver MDT in oligometastatic breast cancer results in durable disease control in a significant proportion of patients. Tumor biology, prior treatment, and extent of disease may be useful to guide the decision to add MDT to standard therapy.</p>
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.